首页> 外文期刊>Cancer Medicine >Combining multimodal imaging and treatment features improves machine learning‐based prognostic assessment in patients with glioblastoma multiforme
【24h】

Combining multimodal imaging and treatment features improves machine learning‐based prognostic assessment in patients with glioblastoma multiforme

机译:多模式影像学和治疗功能的结合可改善多形性胶质母细胞瘤患者基于机器学习的预后评估

获取原文
           

摘要

Background For Glioblastoma (GBM), various prognostic nomograms have been proposed. This study aims to evaluate machine learning models to predict patients' overall survival (OS) and progression‐free survival (PFS) on the basis of clinical, pathological, semantic MRI‐based, and FET‐PET/CT‐derived information. Finally, the value of adding treatment features was evaluated. Methods One hundred and eighty‐nine patients were retrospectively analyzed. We assessed clinical, pathological, and treatment information. The VASARI set of semantic imaging features was determined on MRIs. Metabolic information was retained from preoperative FET‐PET/CT images. We generated multiple random survival forest prediction models on a patient training set and performed internal validation. Single feature class models were created including "clinical," "pathological," "MRI‐based," and "FET‐PET/CT‐based" models, as well as combinations. Treatment features were combined with all other features. Results Of all single feature class models, the MRI‐based model had the highest prediction performance on the validation set for OS (C‐index: 0.61 [95% confidence interval: 0.51‐0.72]) and PFS (C‐index: 0.61 [0.50‐0.72]). The combination of all features did increase performance above all single feature class models up to C‐indices of 0.70 (0.59‐0.84) and 0.68 (0.57‐0.78) for OS and PFS, respectively. Adding treatment information further increased prognostic performance up to C‐indices of 0.73 (0.62‐0.84) and 0.71 (0.60‐0.81) on the validation set for OS and PFS, respectively, allowing significant stratification of patient groups for OS. Conclusions MRI‐based features were the most relevant feature class for prognostic assessment. Combining clinical, pathological, and imaging information increased predictive power for OS and PFS. A further increase was achieved by adding treatment features.
机译:背景对于胶质母细胞瘤(GBM),已经提出了各种预后诺模图。这项研究旨在评估基于临床,病理,基于MRI语义和FET-PET / CT的信息的机器学习模型,以预测患者的总生存期(OS)和无进展生存期(PFS)。最后,评估了添加治疗功能的价值。方法回顾性分析189例患者。我们评估了临床,病理和治疗信息。在MRI上确定了VASARI语义成像特征集。代谢信息保留在术前FET-PET / CT图像中。我们在患者训练集上生成了多个随机生存森林预测模型,并进行了内部验证。创建了单个要素类模型,包括“临床”,“病理学”,“基于MRI”和“基于FET-PET / CT”的模型,以及组合。治疗功能与所有其他功能结合在一起。结果在所有单一要素类模型中,基于MRI的模型在OS(C指数:0.61 [95%置信区间:0.51-0.72])和PFS(C指数:0.61 [ 0.50-0.72])。所有功能的组合确实提高了所有单要素类模型的性能,分别针对OS和PFS的C指标分别为0.70(0.59-0.84)和0.68(0.57-0.78)。添加治疗信息进一步提高了OS和PFS验证集的C指数分别为0.73(0.62-0.84)和0.71(0.60-0.81)的预后性能,从而使OS的患者群体显着分层。结论基于MRI的特征是与预后评估最相关的特征类别。结合临床,病理和影像学信息可提高OS和PFS的预测能力。通过增加治疗功能进一步增加了治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号